Drug Trial Radar · NCT02968927
TB Host Directed Therapy
Last checked: Nov 20, 2026Latest source record: Jan 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Actual
Start
Nov 2016
Primary completion
Sep 2018
Study completion Dec 2020
Sponsor
- Lead sponsor
- The Aurum Institute NPCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.
Conditions
- Tuberculosis
Interventions
Everolimus 0.5 MGDrug
Auranofin 6 MGDrug
Vitamin D3Drug
CC-11050Drug
2HRbZE/4HRbDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAEs and SUSARsTime frame: through day 180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.